GlobeNewswire

Todd Karran to Retire as President, CEO and Board Member of NOVA Chemicals

Share

Calgary, Alberta, Canada , June 18, 2020 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) today announced that Todd Karran, President, CEO and Board Member, has elected to retire, effective August 1, 2020.

Musabbeh Al Kaabi, Chairman of the Board of Directors, said, “On behalf of the Board and shareholder, I would like to thank Todd for his long and devoted service to the company.  There have been a number of important milestones achieved under his leadership and we truly appreciate his commitment to the NOVA family and, not least, ensuring an unwavering focus on safety. We wish him well as he retires from the company.”

A career veteran of NOVA Chemicals, Karran has served as President and CEO since 2015. He has led the company through significant growth and expansion projects including the completion and start-up of a new polyethylene reactor in Alberta, Canada, the decision to expand NOVA Chemicals’ geographical footprint into the US Gulf Coast and building a second Advanced SCLAIRTECHTM technology facility in Ontario, Canada.

“It’s been my pleasure and an honor to work alongside such a talented and passionate team for 35 years. I’m incredibly proud of the work we’ve done together and know that there is a bright future ahead for my friends and colleagues that are working to shape a better world,” stated Karran.

Mr. Al Kaabi added, “After a thorough process to identify a strong and capable successor, the Board of Directors are finalizing arrangements with a talented and experienced leader and expect to be able to make an announcement shortly.”

________________________

About Todd Karran
Todd Karran has been the President and Chief Executive Officer of NOVA Chemicals since 2015. Karran joined NOVA Chemicals in 1985 and has served the company in several roles, such as Chief Financial Officer, Vice President, Corporate Development & Treasurer; Chief Information Officer; Vice President, Applications; and Vice President and Controller, Olefins/Polyolefins.

His 35 years of experience in pipeline, chemical & plastics manufacturing, and international business has helped him support profitable growth for the company.

Karran is a graduate of the Accelerated Accounting program at the Southern Alberta Institute of Technology, and holds a CPA, CMA professional accounting designation in Alberta. He also has an MBA from the Katz School of Business from the University of Pittsburgh and holds a C.Dir chartered director designation from McMaster University and the Conference Board of Canada. Karran has served as a Director of AdvanSix Inc. (NYSE: ASIX, Parsippany, NJ) since 2016.

Todd Karran - Download headshot

About NOVA Chemicals Corporation
NOVA Chemicals develops and manufactures chemicals and plastic resins that make everyday life healthier, easier and safer. Our employees work to ensure health, safety, security and environmental stewardship through our commitment to Sustainability and Responsible Care®. NOVA Chemicals, headquartered in Calgary, Alberta, Canada, is wholly-owned ultimately by Mubadala Investment Company of the Emirate of Abu Dhabi, United Arab Emirates.
Visit NOVA Chemicals on the Internet at www.novachem.com.

##

Media inquiries
Jennifer Nanz
Director, Communications
E-mail: jennifer.nanz@novachem.com


Investor Relations
Patty Masry, Leader, Financial Reporting & Investor Relations
E-mail: Patty.Masry@novachem.com

NOVA Chemicals’ logo is a registered trademark of NOVA Brands Ltd.; authorized use.
Responsible Care® is a registered trademark of the Chemistry Industry Association of Canada.
Advanced SCLAIRTECH™ is a trademark of NOVA Chemicals.

Forward Looking Statements:  This news release contains forward-looking statements regarding finalizing arrangements for Mr. Karran’s successor and the Board of Directors’ expectation that an announcement will be made shortly. By their nature, forward-looking statements require NOVA Chemicals to make assumptions and are subject to inherent risks and uncertainties. NOVA Chemicals’ forward-looking statements are expressly qualified in their entirety by this cautionary statement. In addition, the forward-looking statements are made only as of the date of this news release, and except as required by applicable law, NOVA Chemicals undertakes no obligation to update the forward-looking statements to reflect new information, subsequent events or otherwise.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation19.9.2020 16:25:00 CESTPress release

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3 Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only trea

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma19.9.2020 16:20:00 CESTPress release

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the long

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 202019.9.2020 16:20:00 CESTPress release

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapyFinal overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours expressed PD-L1 and who received Tecentriq plus nab-paclitaxelResults from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel for the treatment of people with metastatic TNBC and whose tumours expressed PD-L1, did not meet its primary endpoint of progression-free survival Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical

Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CESTPress release

Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se. Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol